EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 243 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... December 22, 2020 EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab June 30, 2020 Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 The Largest Randomised Study to Date Points to Low Ipsilateral Breast... June 22, 2023 Load more HOT NEWS Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... Cancer Rehabilitation Starts at Diagnosis: Part II How a Musician Copes With Life With Metastatic Breast Cancer Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with...
